Research monograph · glp-1 receptor agonist (incretin mimetic)
Appetite Regulation Studies
This monograph collects what the published literature reports about GLP-1 S — its mechanisms, the areas it is studied in, its molecular record and the sources behind them. The single substitution that accounts for most of the difference sits at the position where DPP-4 would normally cleave the peptide, which is what extends its duration. Research examines receptor selectivity and appetite-signaling endpoints.
For laboratory research use only — not for human or animal use
Mechanisms
GLP-1 Receptor Agonism
Selective agonism at the GLP-1 receptor, with a sequence roughly 94% identical to the native hormone. Selectivity is the point — it engages one receptor rather than the two or three its newer relatives do.
Central Appetite Regulation
GLP-1 receptors in the hypothalamus and brainstem are the population associated with satiety signalling, which is where appetite endpoints in this literature are measured.
Extended Half-Life Design
The single substitution that accounts for most of the divergence from native GLP-1 sits exactly where DPP-4 would cleave it. Blocking that site is what turns a minutes-long half-life into a useful one.
Studied applications
Body-weight endpoints dominate this literature, measured against placebo and against other agonists in the same class.
Wilding et al. 2021
HbA1c is the primary endpoint, with receptor selectivity the variable distinguishing this compound from dual and triple agonists.
Marso et al. 2016
Outcome trials in this class measure cardiovascular events over years rather than surrogate markers over weeks.
SUSTAIN-6, 2016
Central receptor populations in the hypothalamus and brainstem are studied for satiety signalling rather than peripheral effects.
Davies et al. 2021
What the published work measures
The endpoints reported across the literature for this compound. The figures belong to the individual papers, not to us.
Reference values
Scroll for full molecular data →
| Molecular weight | 4,113.58 g/mol |
|---|---|
| Physical form | Lyophilized powder |
| Documented purity | Quantified by HPLC, reported per lot |
| Storage | -20°C for long-term stability |
| Solubility | Water-soluble |
| Available sizes | 20mg |
FAQ
GLP-1 S is a selective GLP-1 receptor agonist whose sequence is roughly 94% identical to native GLP-1. The single substitution that accounts for most of the difference sits at the position where DPP-4 would normally cleave the peptide, which is what extends its duration. Research examines receptor selectivity and appetite-signaling endpoints.
Published research on GLP-1 S concentrates on Obesity & Weight Management, Type 2 Diabetes & Glycemic Control, Cardiovascular Outcomes and Appetite & Reward Circuitry. Each of those areas is summarised further up this page with the citation it comes from, and the full reference list — 3 indexed publications — sits at the bottom. Study designs and concentrations vary considerably between publications, so the primary sources are worth reading directly.
The literature describes GLP-1 S acting across GLP-1 Receptor Agonism, Central Appetite Regulation and Extended Half-Life Design, reported respectively as GLP-1R, CNS and PK. Those pathways are drawn from preclinical models rather than clinical work, and they describe what has been observed rather than a settled mechanism — the individual pathway cards above cite what each one is based on.
GLP-1 S has a molecular formula of C187H291N45O59 and an average mass of 4113.58 g/mol. It is indexed under CAS 910463-68-2. It ships as lyophilized powder. Those are nominal reference values for the parent compound. The identity of the specific material you receive is confirmed by mass spectrometry and reported on that lot's certificate.
Store the sealed vial at -20°C, protected from light and moisture, and let it reach room temperature before opening so condensation does not form on cold powder. GLP-1 S is water-soluble; reconstitute by directing the diluent down the vial wall rather than onto the powder, then swirl to dissolve rather than shaking. Keep reconstituted solution refrigerated and avoid repeated freeze-thaw cycles — solutions are far less stable than lyophilized powder.
No. GLP-1 S is supplied strictly for in-vitro laboratory research and development. It is not a drug, food, supplement or cosmetic, it has not been evaluated by the FDA, and it is not intended for human or animal consumption, ingestion, injection or any in-vivo use. Ordering confirms you are a qualified researcher or institution purchasing on that basis.
Cited sources
Independent published research indexed from PubMed — not Routine Peptides claims.
Before you order
Every production run is analyzed by an independent laboratory, and the certificate for your lot travels with the order — not a catalog-wide document, and not a summary written by us.
